B Gerber
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
von Minckwitz G, Jackisch C, Kümmel S, Fasching P, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, Hilfrich J, Costa S, Dubsky P, Blohmer J, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). Eur J Cancer 2016; 64:12-21.
17.06.2016Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
17.06.2016Eur J Cancer 2016; 64:12-21
von Minckwitz G, Jackisch C, Kümmel S, Fasching P A, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober Jens, Gerber B, Zahm D M, Hilfrich J, Costa S D, Dubsky P, Blohmer J U, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
Untch M, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Jackisch C, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S. Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe Frauenheilkd 2015; 75:556-565.
17.06.2015Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)
17.06.2015Geburtshilfe Frauenheilkd 2015; 75:556-565
Untch M, Blohmer J-U, Costa S-D, Decker T, Diel I, Fasching P A, Fehm T, Janni W, Lück H-J, Maass N, Scharl A, Beckmann M W, Jackisch C, Thomssen C, Harbeck N, Huober Jens, von Minckwitz G, Gerber B, Kreipe H-H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Loibl S
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
Lindner J, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, Engels K, Huober J, Sinn B, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner B, Gerber B, Gade S, Darb-Esfahani S, von Minckwitz G. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. Ann Oncol 2014; 26:95-100.
29.10.2014Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
29.10.2014Ann Oncol 2014; 26:95-100
Lindner J L, Tesch H, Karn T, Pommerenke F, Liedtke C, Untch M, Müller V, Rack B, Schem C, Engels K, Huober Jens, Sinn B V, Loibl S, Denkert C, Ataseven B, Fasching P A, Pfitzner B M, Gerber B, Gade S, Darb-Esfahani S, von Minckwitz G
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
Deuker J, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann D, Rack B, Salat C, Sattler D, Tio J, von Abel E, Fischer D, Ober A, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer H, Conrad B, Feisel-Schwickardi G, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Christensen B, Burkamp U, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Ruhland F, Stefek A, Köhne C, Meinerz W, Grasshoff S, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Weder P, Steffens C, Lemster S, Schlag R, Müller T, von Minckwitz G, Nekljudova V, Gerber B, GBG/AGO-B study groups, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer J, Mau C, Potenberg J, Schilling J, Fehm T, Hauschild M, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J, Just M, Weiss E, Möbus V, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Khandan F, Kühn T, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kast K, Nestle-Krämling C, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Holms F. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372.
15.09.2014Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
15.09.2014Ann Oncol 2014; 25:2363-2372
Deuker J-U, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann D-M, Rack B, Salat C, Sattler D, Tio J, von Abel E, Fischer D, Ober A, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer H-U, Conrad B, Feisel-Schwickardi G, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Christensen B, Burkamp U, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Ruhland F, Stefek A, Köhne C-H, Meinerz W, Grasshoff S-T, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Weder P, Steffens C-C, Lemster S, Schlag R, Müller T, von Minckwitz G, Nekljudova V, Gerber B, GBG/AGO-B study groups, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer J-U, Mau C, Potenberg J, Schilling J, Fehm T, Hauschild M, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer J U, Just M, Weiss E, Möbus V, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Khandan F, Kühn T, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kast K, Nestle-Krämling C, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Holms F
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
von Minckwitz G, Costa S, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Blohmer J, Hanusch C, Rezai M, Fasching P, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Untch M. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Ann Oncol 2013; 25:81-9.
21.11.2013Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro)
21.11.2013Ann Oncol 2013; 25:81-9
von Minckwitz G, Costa S D, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Blohmer J U, Hanusch C, Rezai M, Fasching P A, Huober Jens, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Untch M
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
Gerber B, Jackisch C, Kunz G, Blohmer J, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 2013; 24:2978-84.
17.10.2013Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
17.10.2013Ann Oncol 2013; 24:2978-84
Gerber B, Jackisch C, Kunz G, Blohmer J U, Huober Jens, Hauschild M, Nekljudova V, Untch M, von Minckwitz G, Solbach C, Kreienberg R, Hanusch C, Loibl S, Eidtmann H, Rezai M, Fasching P A, Tesch H, Eggemann H, Schrader I, Kittel K, German Breast Group Investigators
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J, Budczies J, Mehta K, Fehm T, Huober J, Loibl S, Müller B, Eidtmann H, Schmitt W, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013; 24:2786-93.
22.08.2013Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
22.08.2013Ann Oncol 2013; 24:2786-93
Denkert C, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstösser E, Blohmer J U, Budczies J, Mehta K M, Fehm T, Huober Jens, Loibl S, Müller B M, Eidtmann H, Schmitt W D, Eiermann W, Gerber B, Tesch H, Hilfrich J, von Minckwitz G
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
von Minckwitz G, Kaufmann M, Mehta K, Loibl S, Skacel T, Vescia S, Grasshoff S, Jackisch C, Costa S, Huober J, Hilfrich J, Gerber B, Eidtmann H, Eiermann W, du Bois A, Kümmel S, German Breast Group. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:292-8.
01.02.2008Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
01.02.2008Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:292-8
von Minckwitz G, Kaufmann M, Mehta K M, Loibl S, Skacel T, Vescia S, Grasshoff S-T, Jackisch C, Costa S D, Huober Jens, Hilfrich J, Gerber B, Eidtmann H, Eiermann W, du Bois A, Kümmel S, German Breast Group
Endocrine treatment of metastastic breast cancer
Gerber B, Huober J. Endocrine treatment of metastastic breast cancer. Breast Care 2006; 1:248-251.
01.01.2006Endocrine treatment of metastastic breast cancer
01.01.2006Breast Care 2006; 1:248-251
Gerber B, Huober Jens